3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile
摘要:
The optimization of compounds from the 3-amido-4-anilinoquinolines series of CSF-1R kinase inhibitors is described. The series has excellent activity and kinase selectivity. Excellent physical properties and rodent PK profiles were achieved through the introduction of cyclic amines at the quinoline 6-position. Compounds with good activity in a mouse PD model measuring inhibition of pCSF-1R were identified. (C) 2008 Elsevier Ltd. All rights reserved.
3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile
摘要:
The optimization of compounds from the 3-amido-4-anilinoquinolines series of CSF-1R kinase inhibitors is described. The series has excellent activity and kinase selectivity. Excellent physical properties and rodent PK profiles were achieved through the introduction of cyclic amines at the quinoline 6-position. Compounds with good activity in a mouse PD model measuring inhibition of pCSF-1R were identified. (C) 2008 Elsevier Ltd. All rights reserved.
4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS
申请人:Cook Donald
公开号:US20090054411A1
公开(公告)日:2009-02-26
The invention relates to chemical compounds of formula IA or IB:
or pharmaceutically acceptable salts thereof which possess CSF-1R kinase inhibitory activity and are accordingly useful for their anti-cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti-cancer effect in a warm-blooded animal such as man.
[EN] 4-ANILINOQUINOLINE-3-CARBOXAMIDES AS CSF-1R KINASE INHIBITORS<br/>[FR] 4-ANILINOQUINOLEINE-3-CARBOXAMIDES EN TANT QU'INHIBITEURS DE LA CSF-IR KINASE
申请人:ASTRAZENECA AB
公开号:WO2007119046A1
公开(公告)日:2007-10-25
[EN] The invention relates to chemical compounds of formula IA or IB: formula IA IB or pharmaceutically acceptable salts thereof which possess CSF 1R kinase inhibitory activity and are accordingly useful for their anti cancer activity and thus in methods of treatment of the human or animal body. The invention also relates to processes for the manufacture of said chemical compounds, to pharmaceutical compositions containing them and to their use in the manufacture of medicaments of use in the production of an anti cancer effect in a warm blooded animal such as man. [FR] L'invention porte sur des composés chimiques de formule IA ou IB : IA IB ou sels pharmaceutiquement acceptables de ceux-ci qui possèdent une activité inhibitrice de la CSF-1R kinase et sont, en conséquence, utiles pour leur activité anti-cancer et de ce fait dans des méthodes de traitement du corps humain ou animal. L'invention porte également sur des procédés de fabrication desdits composés chimiques, sur des compositions pharmaceutiques les contenant et sur leur utilisation dans la fabrication de médicaments destinés à être utilisés dans la production d'un effet anti-cancer dans un animal à sang chaud tel que l'homme.
3-Amido-4-anilinoquinolines as CSF-1R kinase inhibitors 2: Optimization of the PK profile
作者:David A. Scott、Kirsten J. Bell、Cheryl T. Campbell、Donald J. Cook、Les A. Dakin、David J. Del Valle、Lisa Drew、Thomas W. Gero、Maureen M. Hattersley、Charles A. Omer、Boris Tyurin、Xiaolan Zheng
DOI:10.1016/j.bmcl.2008.12.044
日期:2009.2
The optimization of compounds from the 3-amido-4-anilinoquinolines series of CSF-1R kinase inhibitors is described. The series has excellent activity and kinase selectivity. Excellent physical properties and rodent PK profiles were achieved through the introduction of cyclic amines at the quinoline 6-position. Compounds with good activity in a mouse PD model measuring inhibition of pCSF-1R were identified. (C) 2008 Elsevier Ltd. All rights reserved.